Pilot study to look at the feasibility of using remote vital sign monitoring app to improve the care of patients being treated at home with highly myelosuppressive chemotherapy.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000780651

Enrollment

Registered

2014-07-21

Start date

2014-08-01

Completion date

2015-06-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a study to determine whether using a remote vital sign monitoring application improves the care in patients being treated with highly myelosuppressive chemotherapy at home. Who is it for? You may be eligible to join this study if you aged 18 years or above and are being treated with highly myelosuppressive chemotherapy. Study details Participants in this study will be using the remote vital sign application device at home for during the time when their white cell count is low (usually day 8-14 of the chemotherapy cycle). The remote vital sign application will be attached to the skin by a patch adhesive and it will monitor vital signs such as body temperature and heart rate. During this time, oral thermometer measurements will also be taken manually and recorded on a data sheet. Information from the device and the manual oral measurements will be collated after the white cell count has recovered, and the patch is removed.

Interventions

The aim of this project is to assess the vital sign monitoring app designed by SecuraHeath (Registered Trademark) to see if it can improve the care of patients receiving very myelosuppressive chemotherapy regimens. To do this we will compare the continuous vital sign monitor with the normal four times a day oral thermometer measurement (both measurements taken from the same patient). The patient wears a patch (which they place on the chest wall) which relays a signal to the smart phone app continuously. The smart phone app relays the message to a central database. The central database is configured with limits which alarm when the data is out of a defined range. The central database can be viewed by the health service. The app is used to monitor the temperature during the period of neutropenia post chemotherapy (usually days 8-14 of the chemotherapy cycle).

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients being treated with highly myelosuppressive chemotherapy (e.g. regimens for high grade lymphoma or leukaemia).

Exclusion criteria

Patients under 18 years of age. Patients with pacemakers.

Outcome results